

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2008 (12.09.2008)

PCT

(10) International Publication Number  
**WO 2008/107422 A1**

(51) International Patent Classification:

A61K 35/12 (2006.01)	G01N 33/53 (2006.01)
C07K 14/52 (2006.01)	A61K 49/00 (2006.01)
A61K 38/19 (2006.01)	C07K 16/28 (2006.01)
C12N 15/11 (2006.01)	A61L 27/22 (2006.01)
A61K 48/00 (2006.01)	

(21) International Application Number:

PCT/EP2008/052578

(22) International Filing Date: 3 March 2008 (03.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2007/0136	2 March 2007 (02.03.2007)	IE
2007/0901	10 December 2007 (10.12.2007)	IE

(71) Applicant (for all designated States except US): NATIONAL UNIVERSITY OF IRELAND, GALWAY [IE/IE]; University Road, Galway (IE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): O'BRIEN, Timothy [IE/IE]; Corcullen, Bushypark, Galway (IE). BARRY, Frank [IE/IE]; 12 Owenriff Park, Oughterard, Co. Galway

(IE). LIEW YIE LOONG, Aaron [MY/IE]; 30 An Logan, Western Distributor Road, Galway (IE). SAMALI, Afshin [IE/IE]; 25B Hawthorn Place, Clybaun Road, Galway (IE). DUFFY, Angela [IE/IE]; 20 Ros Geal, Miller's Lane, Rahoon, Galway (IE).

(74) Agent: GATES, Marie Christina Esther; Tomkins & Co., 5 Dartmouth Road, Dublin, 6, (IE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: OSTEOPONTIN FOR THE PREDICTION AND TREATMENT OF CARDIOVASCULAR DISEASES




Figure 1:

(57) Abstract: Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.

WO 2008/107422 A1



**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

**Title**

Osteopontin for the prediction and treatment of cardiovascular diseases

**Field of the Invention**

5 The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.

**Background to the Invention**

10 The discovery of endothelial progenitor cells (EPCs) by Asahara et al in 1997 has provided an insight into the pathogenesis of many vascular disease states such as ischaemia, restenosis and pulmonary hypertension<sup>1-6</sup>. Urbich et al have recently defined EPCs as highly proliferative non-endothelial cells which are capable of transdifferentiating into endothelial cells<sup>7</sup>. EPCs can be isolated from various sources, including bone marrow, peripheral blood and umbilical cord blood<sup>8-10</sup>. There are two phenotypes of EPCs (early versus late EPCs) which both have distinct proliferative and angiogenic potential<sup>8,11</sup>. The ability to adhere to matrix molecules such as fibronectin, incorporate acLDL and bind lectin remains the commonly used definition for EPCs, but, increasingly, further flow cytometry analysis and immunostaining with various markers  
15 such as haematopoietic markers and endothelial markers are utilised to define EPCs<sup>12-15</sup>.

20 Patients with type 1<sup>16</sup> and type 2<sup>17,18</sup> diabetes mellitus have a lower number of EPCs as compared to healthy volunteers. Patients with type 2 diabetes complicated with peripheral vascular disease have even lower number of EPCs compared to those without complications<sup>18</sup>. EPC number in these patients inversely correlates with glycaemic control<sup>16-18</sup>. EPCs isolated from patients with type 2 diabetes had decreased adhesion to activated endothelial cells, and to matrix molecules such as collagen and fibronectin<sup>17</sup>. EPCs derived from patients with both types of diabetes have impaired ability to form tubules *in vitro*<sup>16,17</sup>. Furthermore, bone marrow mononuclear cells derived from streptozotocin induced diabetic mouse differentiate less efficiently into EPCs *in vitro* and  
25 are less likely to form tubules than those derived from non-diabetic mice<sup>19</sup>. The conditioned media from EPCs isolated from patient with type 1 diabetes has a reduced angiogenic capacity and may contain inhibitors of tubule formation *in vitro*<sup>16</sup>. The  
30

phenotype of EPCs derived from patients with type 1 diabetes also remains unchanged even after culture in normoglycaemic conditions<sup>16</sup>.

Osteopontin (OPN) is an arginine-glycine-aspartic acid (RGD)-containing glycoprotein. It is involved in cell migration, cell survival, regulation of immune cell function, inhibition of calcification and control of tumor cell phenotype<sup>23-25</sup>. Osteopontin enhances tumour growth<sup>26</sup>, and its progression<sup>27</sup>. In the setting of primary non-small cell lung cancer, overexpression of OPN increases the aggressiveness of the tumour<sup>28</sup>. Inhibition of OPN expression by either an inducible short-hairpin RNA vector<sup>29</sup>, RNA interference<sup>30</sup> or antisense oligonucleotides<sup>31</sup> attenuates the aggressiveness of various tumours.

The prevalence and fatality of cardiovascular disease (CVD) worldwide is testament to the inefficiency of current therapeutic regimes. A fundamental element in many cardiovascular diseases is the loss of functional cardiomyocytes. Apoptosis is associated with many cardiovascular conditions, such as myocardial infarction and heart failure, however the precise mechanisms are unknown. We have identified OPN as a therapeutic target in the prevention of cardiomyocyte death and CVD. Management of expression of candidate genes in patients with cardiovascular disease may greatly enhance their life expectancy. More importantly, regulation of expression of these genes in individuals predisposed to CVD may prevent the onset of the disease. In myocardial complications apoptosis has been observed repeatedly in compromised human hearts and has been proven to be a major contributor to cardiomyocyte death during ischemic/reperfusion (I/R) injury and cardiomyopathy (Gottlieb RA, The Journal of Clinical Investigation 1994, Fliss H, Circulation Research 1996).

### **Object of the Invention**

The object of this invention is to assess the number and function of EPCs derived from patients with cardiovascular diseases, including poorly controlled T1DM cardiovascular disease and to understand the mechanisms underlying cardiovascular diseases. A further objective is to provide compositions and methods for use in the prevention and treatment of cardiovascular diseases including T1DM cardiovascular disease, and resultant symptoms such as diabetic ulcers.

### **Summary of the Invention**

According to the present invention there is provided a pharmaceutical composition comprising osteopontin together with a pharmaceutically acceptable carrier or excipient. Such a composition finds use in the treatment of vascular diseases, diabetes-associated vascular disease or complications including cardiovascular diseases arising from such diseases. One example of such a complication is foot ulcers, although there are many others.

As used herein the term 'cardiovascular diseases or complications' includes cardiovascular diseases and diabetes associated vascular complications including conditions such as myocardial infarction, ischemia, peripheral vascular disease, ischemia, cerebrovascular disease, coronary vascular diseases and heart failure and it's underlying causes. Such diseases may be due to the presence of risk factors for these vascular diseases such as diabetes mellitus, dyslipidaemia and hypertension.

In a further aspect, the invention provides a composition for the treatment of cardiovascular complications comprising endothelial progenitor cells (EPCs) or mesenchymal stem cells (MSCs) which have been modified to augment osteopontin gene expression together with a pharmaceutically acceptable carrier or excipient. The cardiovascular disease may be associated with diabetes. Overexpression of osteopontin by EPCs or MSCs can be achieved in a variety of ways known to the person skilled in the art, for example by transfecting the cell with liposome or adenovirus encoding OPN gene. Alternatively, EPCs or MSCs can also be preincubated with recombinant OPN prior to transplantation to provide an activated EPC or MSC. In this context activated stem cells are those that have been pre-treated with OPN which renders them more able to form tubules. Thus supplementation with OPN of OPN deficient cells improves their function.

In a further embodiment an OPN coated stent together with administration of EPC/MSCs could be used to enhance the angiogenic effect. The invention also provides a pharmaceutical composition comprising the gene encoding osteopontin or a mutant thereof also encoding functional osteopontin, together with a pharmaceutically acceptable carrier or excipient.

In a further aspect, the invention provides a method for determining whether a subject has cardiovascular disease or is at risk of developing cardiovascular disease by measuring the level of osteopontin expression in the patient and comparing the level with that of a healthy control. Likewise, the invention provides a method for determining

whether a subject with diabetes has vascular complications, or is at risk of developing diabetes related vascular complications comprising measuring the level of osteopontin expression in the patient and comparing the level with that of a healthy control. The level of osteopontin expression may be measured in any of blood, tissue, EPCs or serum from a patient.

OPN level is increased in hyperglycaemic states. This may be related to the protective role of OPN in this state. Measuring endogenous OPN level in EPCs may be useful since a low OPN level (as shown herein) implies that these subjects are at risk of developing diabetes related vascular complications in the near future even though the complications have not occurred yet, whereas an elevated endogenous OPN level (Loomans' paper) implies the presence of vascular complications. The OPN level is increased in EPCs to enhance therapeutic neovascularisation. However, since the number of EPCs is reduced in patients with vascular complications, the increased endogenous OPN expression in these EPCs may not be sufficient to augment therapeutic neovascularisation. The endogenous OPN may be dysfunctional. Exogenous functional OPN is required to improve EPC function. EPC may serve as a vector for functional OPN transfer to the area of ischaemic injury. The use of additional EPCs overexpressing functional OPN or activated by OPN, may be the solution for non-invasive treatment of T1DM related vascular complications.

The invention also provides methods of treatment of cardiovascular diseases comprising administering to a patient osteopontin, or a polynucleotide encoding osteopontin, endothelial progenitor cells or mesenchymal stem cells which express or overexpress osteopontin or activated EPCs or MSCs. Co-administration of such EPCs or MSC and osteopontin could also be used in these methods. The polynucleotide encoding osteopontin may be incorporated into an endothelial progenitor cell or mesenchymal stem cell and the transformed cell thus produced being usable in a gene therapy technique for the treatment of cardiovascular disease, including diabetes related vascular complications.

In one embodiment patients with peripheral vascular disease (reduced flow due to atherosclerosis in the leg vessels) may be identified and their EPCs may be harvested by blood draw. The gene for OPN may be delivered to the EPCs by non viral or viral means and in turn these modified cells may be delivered to the patient. Delivery to the patient may be through the vasculature using a device or by direct intramuscular delivery.

Similarly the heart muscle or the brain could be treated, although the later would involve only intravascular delivery. The EPCs may be modified virally (e.g. via adenovirus, lentivirus or retrovirus) or non virally (e.g. via electroporation or liposome transmission).

In a still further aspect, the invention provides a method for identifying  
5 compounds useful in the treatment of cardiovascular diseases, comprising assessing the ability of the compound to increase osteopontin expression in a cell in which osteopontin expression is otherwise down-regulated. The OPN expression can be measured for example by using quantitative real-time PCR or ELISA. Compounds useful in the treatment of cardiovascular disease include compounds useful in the treatment of  
10 diabetes related vascular complications

The invention also provides an antibody raised against osteopontin, and a medical device coated with an antibody raised against osteopontin, coated with activated stem cells such as EPCs or coated with stem cells such as EPCs which overexpress osteopontin. MSCs could also be used in this way. The medical device may be a stent, a suture, a  
15 bandage or dressing or a prosthesis.

In the methods of the invention the use of a recombinant osteopontin protein may be achieved by direct administration of osteopontin using viral or non-viral vectors, and genetically modified cells such as EPCs or MSCs may be manipulated to overexpress osteopontin using viral or non-viral methods.

20 Overall the inventors have shown that osteopontin deficiency plays a mechanistic role in diabetic EPC dysfunction and have identified a new therapeutic pathway which can be targeted in diabetic vascular disease. Similarly, the inventors have also shown a role for OPN in cardiovascular disease.

#### **Brief Description of the Drawings**

- 25 **Figure 1:** EPC number in patients with T1DM and healthy volunteers.  
**Figure 2:** Adhesion to collagen in T1DM and healthy volunteers  
**Figure 3:** EPC adhesion to fibronectin in T1DM and healthy volunteers.  
**Figure 4:** EPC adhesion to human umbilical vein endothelial cells.  
**Figure 5:** The number of tubules formed by EPCs derived from patients with T1DM  
30 and healthy volunteers using Matrigel assay.

**Figure 6:** The comparison between the number of tubules formed by EPCs derived from diabetic and non-diabetic rabbits using Matrigel assay. (9.6+/-1.77 vs 13.0+/-0.65: p=0.049).

**Figure 7:** The effect of OPN on the number of tubules formed by EPCs derived from non-diabetic rabbits using Matrigel assay. (13.0+/-0.65 vs 16.5+/-1.15: p=0.039; n=9).

**Figure 8:** The effect of OPN on the number of tubules formed by EPCs derived from diabetic rabbits using Matrigel assay. (9.6+/-1.77 vs 16.6+/-2.19: p=0.010; n=5).

**Figure 9:** The effect of OPN and RGD/RAD on the number of tubules formed by EPCs derived from diabetic rabbits using Matrigel assay.

**Figure 10:** Representative images of LDBF recorded at serial time points before and immediately, 7, 14 and 28 days after surgery in WT and OPN-KO mice.

**Figure 11:** Quantitative analysis of the ischemic/non-ischemic LDBF ratio in WT and OPN-KO mice (n=5 in each group).

**Figure 12:** Representative cytograms showing double staining with anti-Sca-1 and anti-c-kit antibodies for the determination of Sca-1+c-kit+ cells before and 3 days after induction of unilateral hind limb in WT and OPN-KO mice.

**Figure 13:** EPC number in WT and OPN-KO mice before and 3 days after induction of unilateral hind limb ischemia.

**Figure 14:** Western blot analysis of OPN expression in primary neonatal rat cardiomyocytes in response to simulated ischemia.

## **Detailed Description of the Invention**

### **Methods**

#### **Subject recruitment**

Patients with poorly controlled Type 1 Diabetes Mellitus (as defined by HbA<sub>1c</sub> >10%), who are on insulin for more than one year, and not on any other medications were recruited from the Diabetes Day Centre, University College Hospital Galway, Ireland. Ethical approval for this study was obtained from the University College Hospital Galway Clinical Research and Ethical Committee. Patients with micro- or macrovascular complications were excluded from the study. Microvascular complications were defined as the presence of microalbuminuria, diabetic retinopathy and neuropathy. Macrovascular complications were defined as the presence of any previous history of acute coronary syndrome, peripheral vascular disease and cerebrovascular disease. After signing consent,

peripheral blood samples were collected from patients with type 1 diabetes mellitus and healthy volunteers.

#### **Isolation of EPCs**

EPCs were cultured according to previously described techniques. Briefly, mononuclear  
5 cells (MNCs) were isolated by Ficollpaque density centrifugation method. After  
purification with 3 washing steps,  $10 \times 10^6$  or  $2 \times 10^6$  MNCs were plated on fibronectin  
coated, 6-well plates or 4-well glass slides, respectively. Cells were cultured in  
endothelial cell basal medium-2 (Clonetics) supplemented with EGM-2 single aliquots  
(Clonetics) consisting of 5% FBS, vascular endothelial growth factors (VEGF), fibroblast  
10 growth factor-2, epidermal growth factor, insulin-like growth factor-1, and ascorbic acid.  
EPCs were confirmed by dual staining with DiI-acetylated low-density lipoprotein and  
FITC-lectin.

#### **Animal studies**

Diabetes was induced in male New Zealand White rabbit using intravenous injection of  
15 alloxan (150mg/kg). Rabbits with plasma glucose of  $>22$  were included for the study.  
Phlebotomy was performed via the marginal artery under anaesthesia. This study was  
approved by the National University Ireland, Galway (NUIG) Animal Care and Use  
Committee.

#### **EPC Adhesion to Matrix Molecules**

20 Fibronectin (100g/mL) was coated onto 24-well plates for 2 hours at  $37^\circ\text{C}$ . Wells were  
blocked with 1% BSA in PBS for 2 hours and EPCs ( $1 \times 10^5$ ) were added to each well to  
attach for 1 hour. Adherent cells were stained with 0.1% crystal violet and rinsed with  
10% acetic acid to elute the stain from the cells. Attached cells were quantified by  
analyzing the optical density of the media at a wavelength of 600 nm with a microtiter  
25 plate reader.

#### **Adhesion to mature Endothelial Cells**

A monolayer of human umbilical vein endothelial cells (HUVECs) was prepared 48  
hours before the assay by plating  $2 \times 10^5$  cells (passage 5 to 8) in each well of 4-well glass  
slides. HUVECs were pretreated for 12 hours with TNF-alpha (BD Biosciences) (1ng/mL)  
30 or media. EPCs were labeled with diI and  $1 \times 10^5$  cells were added to each well and  
incubated for 3 hours at  $37^\circ\text{C}$ . Nonattached cells were gently removed with PBS, and  
adherent EPCs were fixed with 4% paraformaldehyde and counted by a blinded observer.

**Matrigel tubule assay**

Matrigel (Sigma) was thawed and placed in 4-well glass slides at room temperature for 30 minutes to allow solidification. DiI-labeled EPCs ( $2 \times 10^4$ ) were coplated with  $4 \times 10^4$  human umbilical vein endothelial cells (HUVECs) and incubated with and without  
5 5ug/ml OPN (SIGMA) at 37°C for 12 hours. Tubule formation was defined as a structure exhibiting a length 4 times its width. The number tubules formed was assessed by a blinded counter. To determine if the effect of osteopontin is RGD dependent, different RGD/RAD concentrations were incubated with osteopontin.

**RNA extraction**

10 Total RNA was isolated from day 4 EPCs using RNeasy Mini Kit (Qiagen) as described by the manufacturer. The concentration of isolated total RNA was analyzed using NanoDrop counter. QuantIt DNA High Sensitivity Kit was used to detect presence of any genomic DNA in the total RNA samples.

**Microarray analysis**

15 Microarray analysis were performed using GeneChip Human Genome U133 Plus 2.0 Affymetrix Array. Gene expression profiles were compared between EPCs derived from patients with poorly controlled T1DM and healthy volunteers, with EPCs derived from healthy volunteers as baseline, using MAS5.1 software (Affymetrix). Fold changes were calculated by comparing transcripts between the two groups. K-mean clustering was  
20 used to identify the detected (present or absent) and changed (increased or decreased) calls.

**Primer sequences**

Primers were designed using PrimerExpress software and ordered from SIGMA Genosys (Table. 1).

**25 Real time PCR**

The expression study was performed using a 96 well plate on an ABI Prism 7000 Sequence Detection System (Applied Biosystems) with One Step QuantiTect SYBR Green PCR Kit (Qiagen). The reactions were performed according to the manufacturer's instructions with minor modifications. The PCR program was initiated using sample  
30 volume of 25µls at 50°C for 30 mins for reverse transcription step, 95°C for 15 mins for activation of Taq DNA polymerase and followed by 40 cycles of 15 seconds at 95°C, and 30 seconds at 60°C. The dissociation curves were generated immediately after the real-

time PCR using a temperature range between 60°C and 95°C. Each samples were analyzed in triplicates. All the reactions were further subjected to electrophoresis on 2% agarose gels stained with SyBrGreen dye to confirm the presence of the expected PCR products.

## 5 **Murine Hind Limb Ischaemic Model**

C57BL/6 (WT) and OPN<sup>-</sup>/OPN<sup>-</sup> mice were purchased from Charles River Lab and Jackson Lab respectively. OPN-KO and WT mice aged between 8-10 weeks of age were used. The mice were housed at the Animal Facility in Regenerative Medicine Institute (REMEDI), NCBES, NUIG. All procedures were approved by the Minister of Health and  
10 Children under the Cruelty to Animals Act, 1876. Unilateral hind limb ischemia was created in C57BL/6 and OPN<sup>-</sup>/OPN<sup>-</sup> mice as previously described<sup>32</sup>. In brief, an incision was performed in the skin overlying the middle portion of the left hind limb. After ligation of the proximal end of the femoral artery, the distal portion of the saphenous artery was ligated and the artery as well as, all side branches were dissected free and  
15 excised. The skin was closed using an absorbable suture. Of note, the animals were anesthetized with ketamine and xylazine and maintained with isoflurane.

### **Laser Doppler Blood Flow (LDBF) Assessment**

The hind-limb blood flow on both hind limbs and feet were measured using a laser Doppler blood flow (LDBF) analyzer (PeriScan PIMII, Perimed Inc) immediately before  
20 surgery, and on postoperative days 0, 7, 14, and 28. Blood flow was displayed as changes in the laser frequency using different color pixels. After scanning, stored images were analyzed to quantify blood flow. To avoid data variations caused by ambient light and temperature, hind limb blood flow was expressed as the ratio of left (ischemic) to right (non-ischemic) LDBF.

## 25 **Flow Cytometric Analysis**

All samples were processed within one hour. Live cells were stained with conjugated antibodies to Sca-1, c-kit, and CD31 (BD Biosciences). FACS ARIA Coulter was used to perform the FACS analysis. The frequency of bone marrow cells positive for the above reagents was determined by a two-dimensional side scatter-fluorescence dot plot analysis  
30 of the samples stained with the different reagents, after appropriate gating to exclude granulocytes. Initially, Sca-1<sup>+</sup> bone marrow cells were gated and then the resulting population was examined for dual expression of c-kit. For further analysis, Sca-1<sup>+</sup> cells

were studied for the expression of CD31 using a phycoerythrinconjugated anti-mouse CD31 monoclonal antibody (BD Biosciences), reflecting endothelial differentiation of progenitor cells. Data were processed using the Macintosh CELL Quest software program (BD Biosciences). A single trained operator (T.B.), who was blind to the status  
5 of the animal, performed all flow cytometric analyses throughout the study.

### **Statistical Analysis**

Results are expressed as mean $\pm$ SEM. Comparison between groups was performed by ANOVA. Post hoc analysis and pair wise multiple comparisons were performed using the 2-sided t test with Scheffe adjustment. Probability values <0.05 were considered  
10 statistically significant. All analyses were performed with SPSS software (SPSS Ver. 14.0 Inc).

### **A. Langendorff treatment of ex-vivo hearts**

Male Sprague-Dawley rats (225-250g) were anesthetized, and hearts were rapidly excised and immediately cannulated to a Langendorff perfusion apparatus using a protocol  
15 adapted from Tsuchida *et al.* (*Circulation Research* 1994). Briefly, hearts were perfused with Krebs-Ringer buffer at a constant pressure of 60 mm Hg. All perfused hearts were stabilized for 20 min on the Langendorff apparatus prior to induction of various treatments. Three hearts were used per treatment group (n = 3). Perfused hearts were continuously perfused for 1h 15min following stabilisation. To mimic  
20 ischemia/reperfusion injury non-preconditioned hearts were continuously perfused for 30 min prior to a 30 min exposure to ischemia (stoppage of Kreb's buffer flow) followed by 15 min of reperfusion (resumption of Kreb's buffer flow). Following treatment hearts were immediately removed to Trizol reagent and homogenized (Invitrogen). Following addition of 20 % chloroform samples were mixed by inversion and centrifuged at 12,000  
25 x g for 15 min at 2-8 °C. The RNA was removed and added to an Eppendorf tube containing 0.5 ml isopropanol and vortexed vigorously to precipitate the RNA. After a 10 min incubation at room temperature, the RNA was pelleted by centrifugation at 12,000 x g for 10 min and washed in 1 ml of 75 % ethanol. RNA was pelleted by centrifugation at 7,500 x g for 5 min, the supernatant removed and the pellet allowed to air-dry at room  
30 temperature for 10 min. The pellet was subsequently resuspended in 50  $\mu$ l of DEPC treated water. RNA was quantified by spectroscopy, based on its absorbance at 260 nm (UV absorbance range). Quantitative PCR was carried out with 2  $\mu$ g RNA and Oligo (dT)

12-18 (Invitrogen) using AMV Reverse Transcriptase (Sigma). Primers to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Osteopontin were designed to published mRNA sequences from the National Centre for Biotechnology Information (NCBI) using Primer Express software (Applied Biosystems, Foster City, CA) and sequence specificity was confirmed by performing a BLAST (NCBI) search. Primer sets were synthesized by MWG Biotech (Ebersberg, Germany).

cDNA quantification standards, containing a known number of cDNA copies of each gene, were prepared by purifying PCR products for each gene using the QIAGEN Qiaquick gel extraction kit. These purified products were then quantified by spectroscopy and appropriate dilutions were made.

Amplification reactions were carried out in real-time, with separate reactions set up for each primer set, each containing 12.5 µl of 1x SYBR Green I PCR Master Mix (Applied Biosystems), 12.5 nM of each primer and 2.5 µl template (1 in 50 dilution of cDNA) in a final volume of 25 µl. Amplification reactions were performed in 96-well optical reaction plates on the ABI 7000. A dissociation curve was generated for each primer set at the end of each run and PCR products were run on 2 % agarose gels to confirm the size of the product and the specificity of the primers. cDNA copy numbers for all differentially regulated genes were generated from their respective standard curves and normalised to the housekeeping gene GAPDH. A fold increase was calculated relative to the expression levels of the perfused sample. Real-time RT-PCR was carried out for each of the conditions in triplicate and results were then analysed using a one-way ANOVA followed by Scheffe's test using the statistical package SPSS for Windows version 12.0.1 (SPSS Inc., Chicago, Ill, USA).

**B. Ischemia in primary neonatal cardiomyocytes:**

Primary cultures of neonatal cardiomyocytes were isolated from 1-4 day old Sprague Dawley rats. Briefly, rats were euthanized and hearts excised. After scalpel homogenization, overnight trypsin digestion at 4 °C and a collagenase treatment for 20 min at 37°C, cardiomyocytes were enriched by Percoll gradient centrifugation (Amersham) and plated at a density of  $1 \times 10^5$  /ml in DMEM/F12 medium supplemented with 10% newborn calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate (Gibco-BRL), 5% insulin transferrin selenite (ITS) liquid supplement

media, 100  $\mu$ M 5-Bromo-2-deoxyuridine on culture plates coated with 0.2% gelatin. Cells were cultured at 37°C and 5% CO<sub>2</sub>.

To mimic endogenous ischemia, cultures were exposed to hypoxic conditions (O<sub>2</sub>/N<sub>2</sub>/CO<sub>2</sub>, 0.5:94.5:5), using a hypoxia gas chamber (Ruskin) in the absence of glucose and serum, using glucose-free DMEM (Gibco-BRL) supplemented with 10 mM 2-deoxyglucose, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 1 mM sodium pyruvate, 5% ITS liquid supplement media.

Cells were lysed in whole cell lysis buffer (20 mM HEPES, pH 7.5, 350 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.5 mM EDTA, 0.5 mM EGTA, 1% Igepal-630, 0.5 mM dithiothreitol (DTT), 100  $\mu$ M PMSF and 1  $\mu$ g/ml pepstatin). Cellular proteins were separated by electrophoresis on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes. After blocking (5% non-fat milk, 0.05% Tween-20 in PBS), blots were incubated with antibodies to ostiopontin and were visualised using horseradish peroxidase-conjugated secondary antibodies (Pierce) were used at a 1:5,000 dilution. Protein bands were detected with SuperSignal Ultra Chemiluminescent Substrate (Pierce) on X-ray film (Agfa).

## Results

### Subject recruitment

Four patients with Type 1 Diabetes Mellitus and four age-and gender-matched healthy volunteers were recruited (Table 2).

### Assessment of EPC number

Patients with T1DM have lower number of EPCs as compared to healthy volunteers (244 $\pm$ 20 vs 334 $\pm$ 7, p=0.02) (Figure 1).

### Adhesion to matrix molecules

Patients with T1DM have normal adhesion to collagen (1.00 $\pm$ 0.11 vs 1.34 $\pm$ 0.15, p=0.13) (Figure 2) and fibronectin (1.65 $\pm$ 0.44 vs 2.13 $\pm$ 0.20, p=0.16) (Figure 3).

### Adhesion to endothelial cells

The effect of diabetes on EPC adhesion to endothelial cells was next assessed in quiescent endothelial cells and after exposure to TNF- $\alpha$ . EPCs derived from patients with poorly controlled T1DM demonstrated normal adhesion to quiescent endothelial cells (7.01 $\pm$ 0.91 vs 7.79 $\pm$ 0.68, p=0.54) but impaired adhesion to activated endothelial cells (11.05 $\pm$ 0.01 vs 21.03 $\pm$ 1.13, p=0.001) (Figure 4).

**Tubule Formation using EPCs Derived from Patients with T1DM:**

Formation of tubules *in vitro* a measure of the ability of EPC to participate in angiogenesis was next assessed. EPCs derived from patients with T1DM had impaired ability to form tubules compared to controls (1.7+/-0.9 vs 9.8+/-1.8, p=0.01) (Figure 5).

- 5 This defect was also seen in an animal model of insulin deficient diabetes mellitus when EPCs derived from alloxan-induced diabetic rabbits also showed an impaired ability to form tubules as compared to the EPCs derived from non-diabetic control rabbits (9.6+/-1.77 vs 13.0+/-0.65: p=0.049) (Figure 6).

**Expression of Osteopontin in EPCs from Patients with Poorly Controlled Diabetes Mellitus:**

Using real time PCR, it was demonstrated that OPN expression is reduced in EPCs derived from patients with poorly controlled diabetes mellitus as compared to healthy volunteers.

**Effect of OPN Supplementation on Tubule Formation:**

- 15 Having demonstrated reduced expression of OPN in EPCs derived from patients with poorly controlled T1DM, it sought to determine whether exposure of EPCs to OPN could reverse this defect. To do this, the effect of OPN supplementation on EPC function *in vitro* was assessed. Incubation with OPN augmented the number of tubules formed by EPCs derived from non-diabetic rabbits (13.0+/-0.65 vs 16.5+/-1.15: p=0.039; Figure 7).
- 20 Incubation with OPN also augmented the number of tubules formed by EPCs derived from diabetic rabbits (9.88+/-2.48 vs 16.56+/-2.21; p=0.01) (Figure 8).

**The Effect of OPN on EPC Function is RGD-Dependent.**

Next, investigations were made to determine if the mechanism of OPN action is RGD-dependent. EPCs were co-incubated with OPN and RGD or RAD (Scrambled peptide).

- 25 Co-incubation of EPCs with OPN and RGD, but not RAD, was associated with impaired EPC tubule formation. The results of this experiment show that the effect of OPN on EPC function is RGD-dependent (Figure 9).

**Microarray analysis and realtime PCR**

Microarray analysis demonstrated that osteopontin was downregulated in the EPCs derived from the diabetic subjects. This was further validated using realtime PCR. The mean fold change were compared with the microarray results (Table 3).

30

**Ischemia-Induced Angiogenesis in OPN-KO Mice:**

To study the role of OPN in angiogenesis in vivo, the extent of angiogenesis in a murine model of unilateral hind limb ischemia was assessed. The blood flow was assessed in the WT and OPN-KO mice before and after the procedure. In OPN-KO mice, measurement of the LDBF ratio between the ischemic and the non-ischemic limb indicated that restoration of perfusion in the ischemic hind limb was significantly impaired. At day 7, 14 and 28 after surgery, LDPF ratio was reduced in the OPN-KO mice,  $0.31\pm 0.07$  versus  $0.68\pm 0.11$  ( $P=0.021$ ),  $0.32\pm 0.03$  versus  $0.54\pm 0.05$  ( $p=0.006$ ) and  $0.45\pm 0.06$  versus  $1.09\pm 0.13$  ( $P=0.002$ ) for the WT mice respectively (Figure 10 and 11).

**Impairment of Angiogenesis is not due to Decreased EPC Recruitment:**

Next, the role of EPC recruitment in the pathogenesis of the impaired angiogenesis observed in OPN knockout mouse was explored. For this, circulating EPC numbers were measured before and after induction of hind limb ischemia in OPN knockout and wild type animals. Flow cytometry analysis of EPC number was performed before and three days after the induction of hind limb ischemia. At day zero there were no differences in EPC number between both groups. Furthermore, EPC numbers increased in the OPN knockout mice 3 days after induction of hind limb ischemia ( $0.33\pm 0.05$  on day 0 versus  $0.55\pm 0.05$  on day 3;  $p=0.036$ ). This result suggests that OPN is not implicated in EPC mobilization. In contrast, EPC numbers did not increase 3 days after induction of hind limb ischemia in control mice (Figure 12 and 13).

**A. Langendorff treatment of ex-vivo hearts**

Osteopontin expression levels, as determined by realtime PCR, were decreased 5.14 fold in ischemic/reperfused rat heart in comparison with expression levels in the perfused sample.

**B. Ischemia in primary neonatal cardiomyocytes:**

In rat neonatal cardiomyocytes primary cultures, subjected to conditions to simulate endogenous ischemia conditions, osteopontin protein expression levels were reduced, as determined by Western blot analysis (see Fig 14.), in comparison to cardiomyocytes cultured under normal conditions. Osteopontin expression levels, measured on 2, 8, 12 and 24 hours, did not recover to pre-ischemia levels.

In summary, OPN mRNA and protein levels drop in response to ischemia or ischemia reperfusion.

**Discussion**

EPC number and function can be affected by various factors<sup>15</sup>. Reduced EPC number were demonstrated in patients with Type 1 and Type 2 DM<sup>16,17</sup>. However, microvascular complications were not excluded in these studies. It has recently been shown that diabetic retinopathy increases EPC number<sup>20,21</sup>. For this reason, a homogeneous population without diabetic retinopathy and other complications were chosen. It was desired to observe the effect of hyperglycaemia without other confounding factors in human with T1DM.

The data showed that EPCs derived from patients with uncomplicated Type 1 Diabetes Mellitus have a reduced number. These cells showed normal adhesion to collagen and fibronectin. They also showed normal adhesion to quiescent endothelial cells but impaired adhesion to activated endothelial cells. EPCs derived from patients with T1DM have impaired ability to form tubules. These data were consistent with previous studies<sup>16,17</sup>. The role of OPN in EPC dysfunction in diabetes mellitus has been examined. It has been demonstrated for the first time that OPN expression was markedly reduced in EPCs isolated from subjects with poorly controlled T1DM. This result is the opposite of the effect observed by Loomans et al using microarray analysis<sup>22</sup>. The reason for the discrepancy is unclear but may be due the patient population studied. Furthermore, it has been demonstrated that EPC dysfunction was reversed when cells from diabetic animals were cultured in the presence of recombinant OPN. The effect of OPN on EPC function was also seen in cells from non-diabetic animals in which increased tubule formation was observed. Thus the invention could allow treatment of diseases with are associated with poor tubule formation, or problems with angiogenesis, which includes peripheral vascular disease, ulcer, ischaemic heart disease, and cerebrovascular disease, and subarachnoid haemorrhage secondary to cerebral aneurysm and diabetic retinopathy. The effect of OPN on EPC function was reversed by RGD but not RAD showing the OPN effect is RGD-dependent.

The role of OPN in angiogenesis was next explored using an OPN knockout mouse. It was demonstrated that the restoration of perfusion in the ischemic hind limb was significantly impaired in OPN-KO mice. At day 7 after surgery, LDPF ratio in the OPN-KO mice was approximately half that of the WT mice. This impairment in blood flow recovery persisted up to 28 days after the surgery, suggesting that the absence of OPN impairs neovascularisation in the murine model of unilateral hind limb ischemia. This

defect could be due to decreased mobilization or impairment of EPC incorporation into new vessels at the site of ischemia. The results show increased circulating levels of EPCs after hind limb ischemia in the OPN knockout suggests that impaired mobilization is not the mechanism. This hypothesis is supported by data from Ballard *et al* who have shown  
5 that the expression of OPN did not differ from baseline up to seven days after the induction of mid-dorsal cutaneous wound in diabetic mice. The OPN level subsequently increased at day 7 and remained constitutively higher for a further four days. The authors suggested that the low expression of OPN in diabetic mice may be in part responsible for the delayed healing of wounds in diabetic mice<sup>33</sup>. Therefore, reduced OPN expression in  
10 diabetic EPC may explain the propensity of diabetic subjects to macrovascular complications.

Osteopontin exists as a secreted cytokine or adhesion molecule constitutively expressed in healthy myocardium. Its expression is increased in non-myocytes following myocardial infarction to protect cellular viability and aid adaptive remodelling. Loss of  
15 osteopontin impairs compensatory fibrosis and hypertrophy leading to decreased cardiac performance. Osteopontin expression is also markedly increased in cardiomyocytes by myocardial infarction and heart failure. The mechanism of osteopontin cardioprotection is largely unknown. Osteopontin suppresses cytokine-induced nitric oxide synthase expression, preventing nitric oxide production and contractile impairment. Cellular  
20 signalling is mediated through cell surface integrin receptor binding. Integrin receptors communicate changes in the extracellular matrix to the cytoskeleton. Increased expression of osteopontin is accompanied by the increased expression of its cardiac-receptor  $\beta 1$  integrin during hypertrophy. Anti-integrin antibody blocked angiotensin II induced cardiac remodelling an effect also blocked by anti-osteopontin antibody,  
25 suggesting signalling of angiotensin II proceeds via osteopontin.

In osteopontin-deficient cardiac fibroblasts oxidative stress induced necrosis unlike wild type cells where apoptosis was predominant. This necrotic death was reduced on endogenous re-expression of osteopontin. However, *in vivo* study of myocardial infarcted mouse hearts, have shown osteopontin deficient hearts to have the same number  
30 of apoptotic myocytes as wild type hearts.

## Conclusion

EPC dysfunction in diabetes mellitus is associated with reduced OPN expression and can be reversed by OPN supplementation, which may explain why diabetic subjects are more prone to vascular complications. Furthermore the studies in the OPN knockout animals confirm the crucial role of OPN in angiogenesis. The results suggest that this effect may be related to lower OPN expression in EPCs. EPC dysfunction in diabetes mellitus is due to reduced OPN expression identifying a new therapeutic target for this disorder.

The words “comprises/comprising” and the words “having/including” when used herein with reference to the present invention are used to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination.

#### References

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. *Science*. 1997;275:964-7.

2. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. *Proc Natl Acad Sci U S A*. 2000;97:3422-7.

3. Kubota Y, Kishi K, Satoh H, Tanaka T, Nakajima H, Nakajima T. *Cell Transplant*. 2003;12:647-57.

4. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, Pratt RE, Mulligan RC, Dzau VJ. *Circulation*. 2003;108:2710-5.

5. He T, Smith LA, Harrington S, Nath KA, Caplice NM, Katusic ZS. *Stroke*. 2004;35:2378-84.

6. Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y. *Tissue Eng*. 2004;10:771-9.

7. Urbich C, Dimmeler S. *Trends Cardiovasc Med*. 2004;14:318-22.

8. Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, Simari RD. *Circ Res*. 2003;93:1023-5.

9. Eggermann J, Kliche S, Jarmy G, Hoffmann K, Mayr-Beyrle U, Debatin KM, Waltenberger J, Beltinger C. *Cardiovasc Res*. 2003;58:478-86.
10. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. *Clin Invest*. 2000;105:71-7.
11. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park  
5 YB. *Arterioscler Thromb Vasc Biol*. 2004;24:288-93.
12. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, Yoder MC. *Blood*. 2004;104:2752-60.
13. Walenta K, Friedrich EB, Sehnert F, Werner N, Nickenig G. *Biochem Biophys Res Commun*. 2005;333:476-82.
- 10 14. Bellik L, Ledda F, Parenti A. *FEBS Lett*. 2005;579:2731-6.
15. Liew A, Barry F, O'Brien T. *Bioessays*. 2006;28:261-70.
16. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. *Diabetes*. 2004;53:195-9.
17. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP,  
15 Gurtner GC. *Circulation*. 2002;106:2781-6.
18. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A. *J Am Coll Cardiol*. 2005;45:1449-57.
19. Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D'Agostino D, Jannausch M. *J Bone Miner Res*. 1998;13:695-705.
- 20 20. Asnaghi V, Lattanzio R, Mazzolari G, Pastore MR, Ramoni A, Maestroni A, Ruggieri D, Luzi L, Brancato R, Zerbini G. *Diabetologia*. 2006.
21. Fadini GP, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A, Avogaro A. *Diabetes Care*. 2006;29:714-6.
22. Loomans CJ, De Koning EJ, Staal FJ, Rabelink TJ, Zonneveld AJ. *Antioxid Redox  
25 Signal*. 2005;7:1468-75.
23. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE. *Ann N Y Acad Sci*. 1995;760:127-42.
24. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. *PLoS Med*. 2005;2:e70.
- 30 25. Uede T, Katagiri Y, Iizuka J, Murakami M. *Microbiol Immunol*. 1997;41:641-8.
26. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K, Fukuchi Y. *Cancer Lett*. 2003;198:107-17.

27. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G. *J Invest Dermatol*. 2005;124:1044-52.
28. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y. *Clin Cancer Res*. 2005;11:4646-52.
- 5 29. Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T, Shimada Y. *Clin Cancer Res*. 2006;12:1308-16.
30. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC. *Carcinogenesis*. 2005;26:741-51.
31. Muramatsu T, Shima K, Ohta K, Kizaki H, Ro Y, Kohno Y, Abiko Y, Shimono  
10 M. *Cancer Lett*. 2005;217:87-95.
32. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM. *Am J Pathol*. 1999; 154: 355-63
33. Ballard VL, Sharma A, Duignan I, Holm JM, Chin A, Choi R, Hajjar KA, Wong SC, Edelberg JM. *Faseb J*. 2006; 20:717-9 ()
- 15 34. Tsuchida *et al*. *Circulation Research* 1994.
35. Gottlieb RA, *The Journal of Clinical Investigation* 1994, Fliss H, *Circulation Research* 1996

Gene	Length	Start	Sequence (5'-3')
<b>OPN</b>	114	12	CAGAGCACAGCATCGTCGG
		125	GGCAAAGCAAATCACTGCAA
<b>Cyclophilin A</b>	103	378	TGCTGGACCCAACACAAATG
		480	CATGCCTTCTTTCACTTTGCC

**Table 1:** Primer sequences for Real-Time PCR.

5

	T1DM	Healthy volunteers	P-value
Age (years)	22.3+/-4.3	22.8+/-2.1	NS
Gender	3F:1M	3F:1M	NS
HbA1c(%)	12.5+/-1.5	NA	
Duration of DM (Years)	7+/-2.3	NA	

**Table 2:** Subjects' characteristics.

10

Gene	Gene code	Microarray	Realtime PCR
OPN	M83248	-9.6	-28.54

**Table 3:** Comparison of the osteopontin gene expression (fold changes) between microarray and realtime PCR results.

15

Gene	Forward 5' – 3'	Reverse 5' – 3'	Product Size bp
Osteopontin	CGATGGAGACCATGCAGAGA	GCTTGTGTGCTGGCAGTGA	105
GAPDH	CCAGCAAGGATACTGAGAGCAA	GGATGGAATTGTGAGGGAGATG	101

5

**Table 4: Oligonucleotide Primers**

10

Gene	Q PCR	Comparison
Osteopontin	- 5.14	I/R vs Perfused

**Table 5 – Altered gene expression in response to I/R when compared to perfused hearts**

15

**CLAIMS:**

1. A pharmaceutical composition comprising activated endothelial progenitor cells or mesenchymal stem cells together with a pharmaceutically acceptable carrier or excipient.
- 5 2. A pharmaceutical composition comprising endothelial progenitor cells or mesenchymal stem cells which express or overexpress osteopontin together with a pharmaceutically acceptable carrier or excipient.
3. A pharmaceutical composition comprising osteopontin together with a pharmaceutically acceptable carrier or excipient.
- 10 4. A pharmaceutical composition comprising the gene encoding osteopontin or a mutant thereof also encoding functional osteopontin, together with a pharmaceutically acceptable carrier or excipient.
5. A pharmaceutical composition comprising activated endothelial progenitor cells or activated mesenchymal stem cells.
- 15 6. A pharmaceutical composition as claimed in claim 5 further comprising osteopontin.
7. Use of endothelial progenitor cells or mesenchymal stem cells which express or overexpress osteopontin in the preparation of a medicament for the treatment of cardiovascular disease and associated complications including and diabetes associated  
20 vascular complications.
8. Use of osteopontin in the preparation of a medicament for the treatment of cardiovascular disease and associated complications including diabetes associated vascular complications.
9. Use of a gene encoding osteopontin in the preparation of a medicament for the  
25 treatment of cardiovascular disease and associated complications including diabetes associated vascular complications.
10. Use of activated endothelial progenitor cells or activated mesenchymal stem cells in the preparation of a medicament for the treatment of cardiovascular disease and associated complications, including diabetes associated vascular complications.

11. Use as claimed in claims 7 to 10 wherein the cardiovascular disease and diabetes associated vascular complications is selected from myocardial infarction, coronary vascular disease, peripheral vascular disease, ischemia, cerebrovascular disease, heart failure.
- 5 12. An activated endothelial progenitor cell or activated mesenchymal stem cell which expresses or overexpresses osteopontin.
13. An activated endothelial progenitor cell or activated mesenchymal stem cell as claimed in claim 12 which is genetically modified to augment osteopontin gene expression.
- 10 14. An activated endothelial progenitor cell or activated mesenchymal stem cell as claimed in claim 12 which has been activated by osteopontin.
15. A method for determining whether a subject with diabetes has diabetes related vascular complications, or is at risk of developing diabetes related vascular complications comprising measuring the level of osteopontin expression in the subject, comparing the  
15 level of osteopontin expression with a level of osteopontin expression associated with a control subject who does not have diabetes, wherein a lower level of osteopontin expression correlates with either diabetes associated vascular complications or an increased risk of developing diabetes related vascular complications, in the subject.
16. A method for determining whether a subject has cardiovascular disease or is at  
20 risk of developing cardiovascular disease comprising measuring the level of osteopontin expression in the subject, comparing the level of osteopontin expression with a level of osteopontin expression associated with a control subject who does not have cardiovascular disease, wherein a lower level of osteopontin expression correlates with either cardiovascular disease or an increased risk of developing cardiovascular disease, in  
25 the subject.
17. The method of claim 15 or 16, wherein the level of osteopontin expression is measured in blood, serum, tissue or cells.
18. The use of a gene encoding osteopontin in the manufacture of a medicament for the treatment of cardiovascular disease or diabetes associated vascular complications by  
30 gene therapy.

19. A method of treating cardiovascular disease and diabetes associated vascular complications comprising administering to a patient a pharmaceutically effective amount of osteopontin.
20. A method of treating cardiovascular disease and diabetes associated vascular complications comprising administering to a patient a pharmaceutically effective amount of a polynucleotide encoding osteopontin.
21. A method of treating cardiovascular disease and diabetes associated vascular complications comprising administering to a patient an endothelial progenitor cell or mesenchymal stem cell which expresses or overexpresses osteopontin.
22. A method of treating cardiovascular disease and diabetes associated vascular complications comprising administering to a patient an endothelial progenitor cell or mesenchymal stem cell which has been activated by osteopontin.
23. A method of treating cardiovascular disease and diabetes associated vascular complications comprising administering to a patient a gene encoding osteopontin or a mutant thereof also encoding functional osteopontin.
24. A method as claimed in claim 20 wherein the polynucleotide encoding osteopontin is administered in an endothelial progenitor cell as part of a gene therapy technique.
25. A method as claimed in any one of claims 18 to 24 wherein the cardiovascular disease or diabetes related vascular complication is selected from coronary vascular disease, peripheral vascular disease, ischemia, cerebrovascular disease, heart failure and myocardial infarction.
26. A method for identifying compounds for the treatment of cardiovascular diseases such as coronary vascular disease, peripheral vascular disease, ischemia, cerebrovascular disease, heart failure, myocardial infarction and diabetes associated vascular complications, comprising contacting a test compound with cells in which osteopontin expression is down regulated and determining the effect of the candidate compound on the expression of osteopontin.
27. Use of osteopontin as an angiogenic factors to treat cardiovascular diseases such as coronary vascular disease, peripheral vascular disease, ischemia, cerebrovascular

disease, heart failure, myocardial infarction and diabetes associated vascular complications.

28. Use as claimed in claim 27 wherein the use is of a recombinant osteopontin protein, direct administration of osteopontin, or genetically modified cells such as EPCs  
5 or MSCs to overexpress osteopontin, or EPCs or MSCs activated by osteopontin treatment.

29. An antibody raised against osteopontin.

30. A medical device coated with an antibody raised against osteopontin, coated with  
activated endothelial progenitor cells or activated mesenchymal stem cells or coated with  
10 endothelial progenitor cells or mesenchymal which overexpress osteopontin.

31. A medical device as claimed in claim 30 selected from a stent, a suture, a bandage  
or dressing or a prosthesis.

TOMKINS & CO





Figure 1:



5 Figure 2:




Figure 3:




Figure 4:

5




Figure 5:




Figure 6:

5




Figure 7:




Figure 8:

5




Figure 9:




Figure 10.





Figure 11.

10/11



5

Figure 12.





Figure 13.

5



10 Figure 14.

15

**INTERNATIONAL SEARCH REPORT**

International application No  
PCT/EP2008/052578

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>				
INV. A61K35/12	C07K14/52	A61K38/19	C12N15/11	A61K48/00
G01N33/53	A61K49/00	C07K16/28	A61L27/22	

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/060779 A (UNIV CASE WESTERN RESERVE [US]; LAUGHLIN MARY J [US]; POMPILI VINCENT) 8 June 2006 (2006-06-08) abstract page 2, lines 5-27 page 9, line 35 - page 14, line 8 page 26, lines 20-26 page 31, line 25 - page 35, line 35 page 40, line 20 - page 41, line 23; claims 58-61	1-5,7, 10-14, 30,31
X	WO 2007/012764 A (INST VAISSEUX ET DU SANG [FR]; UNIV PARIS 7 DENIS DIDEROT [FR]; FOUBE) 1 February 2007 (2007-02-01) page 4, line 22 - page 6, line 14 page 8, lines 16-26 page 14; examples 2-4	1,5,10, 11
	----- -/-- -----	

Further documents are listed in the continuation of Box C.  See patent family annex.

\* Special categories of cited documents :

*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document but published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
*O* document referring to an oral disclosure, use, exhibition or other means	*&* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  17 June 2008	Date of mailing of the international search report  01/07/2008
---	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Mateo Rosell, A
---	---

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/052578

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2006/130690 A (JOSLIN DIABETES CT INC [US]; TSENG YU-HUA [US]) 7 December 2006 (2006-12-07) abstract page 4, lines 14-31 page 8, lines 1-10 page 12, lines 18-32 page 20, lines 8-34; examples 1-4</p>	1, 30, 31
X	<p>II MASA AKI ET AL: "Accelerated reendothelialization in ApoE knockout mice is mediated by activated bone marrow-derived endothelial progenitor cells" CIRCULATION, vol. 112, no. 17, Suppl. S, October 2005 (2005-10), page U219, XP008092673 &amp; 78TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 13 -16, 2005 ISSN: 0009-7322 abstract</p>	1, 5, 10, 11
X	<p>JP 2004 222836 A (TISSUE ENGINEERING INITIATIVE; YOSHIKAWA TAKA AKI; SEISHINKAI KOORIYAMA) 12 August 2004 (2004-08-12) the whole document -&amp; DATABASE WPI Derwent Publications Ltd., London, GB; AN 2004-606679 XP002484323 TISSUE ENGINEERING INITIATIVE ; BY YOSHIKAWA T: "MANUFACTURE CULTURE LAYER STEM CELL PRESENCE OESTROGEN IMPREGNATE OBTAIN ACTIVATE ARTIFICIAL SKIN SUBSTITUTE MATERIAL" abstract</p>	1, 30, 31
X	<p>WO 03/046135 A (UNIV LELAND STANFORD JUNIOR [US]; CHABAS DOROTHEE [FR]; STEINMAN LAWRE) 5 June 2003 (2003-06-05) abstract page 1, lines 14-17 page 4, lines 19-25 page 24, line 10 - page 27, line 3; claims 1, 11</p>	3, 4

-/--

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/052578

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2007/024649 A (CELL MEDICAL INC X [US]; BAUMBACH WILLIAM R [US]; SHANKAR HARIHARAN [U] 1 March 2007 (2007-03-01) abstract page 3, line 5 - page 4, line 22 page 9, lines 20-29 page 11, lines 12-24 page 12, line 16 - page 17, line 12; examples 1-4	29-31
X	US 6 414 219 B1 (DENHARDT DAVID T [US] ET AL) 2 July 2002 (2002-07-02) abstract column 2, line 61 - column 3, line 7; example 3	29
Y	TAKAGI H ET AL: "Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization" JAPANESE JOURNAL OF OPHTHALMOLOGY 2002 JP, vol. 46, no. 3, 2002, pages 270-278, XP002484315 ISSN: 0021-5155 abstract page 274, left-hand column, paragraph 2 - right-hand column, paragraph 1 page 275, right-hand column, last paragraph	8,9, 18-20, 23-25,28
Y	ASOU Y ET AL: "Osteopontin facilitates angiogenesis, accumulation of osteoclastst and resorption in ectopic bone" ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 142, no. 3, 1 January 2001 (2001-01-01), pages 1325-1332, XP002994514 ISSN: 0013-7227 abstract page 1327, right-hand column, paragraph 2 - page 1329, left-hand column, paragraph 1 page 1330, right-hand column, paragraph 2 - page 1331, left-hand column, paragraph 1	8,9, 18-20, 23-25,28
Y	GATTORNO M ET AL: "Synovial expression of osteopontin correlates with angiogenesis in juvenile idiopathic arthritis" RHEUMATOLOGY 2004 GB, vol. 43, no. 9, September 2004 (2004-09), pages 1091-1096, XP002484316 ISSN: 1462-0324 abstract page 1095, left-hand column, paragraph 1 - right-hand column, last paragraph	8,9, 18-20, 23-25,28

-/--

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/052578

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>HAMADA Y ET AL: "Angiogenic activity of osteopontin-derived peptide SVVYGLR"            BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC.            ORLANDO, FL, US,            vol. 310, no. 1,            10 October 2003 (2003-10-10), pages 153-157, XP004457198            ISSN: 0006-291X            abstract            page 154, left-hand column, paragraph 5 -            page 156, left-hand column, paragraph 3</p>	<p>8,9,            18-20,            23-25,28</p>
Y	<p>NOIRI E ET AL: "Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene"            KIDNEY INTERNATIONAL 1999 US,            vol. 56, no. 1, 1999, pages 74-82,            XP002484317            ISSN: 0085-2538            abstract            page 76, right-hand column, paragraph 2 -            page 81, right-hand column, paragraph 2</p>	<p>8,9,            18-20,            23-25,28</p>
Y	<p>ELLISON J A ET AL: "MATRIX REMODELING AFTER STROKE DE NOVO EXPRESSION OF MATRIX PROTEINS AND INTEGRIN RECEPTORS"            ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES,            NEW YORK, NY, US,            vol. 890, 1 January 1999 (1999-01-01),            pages 204-222, XP001029484            ISSN: 0077-8923            abstract            page 209, paragraph 1 - page 215,            paragraph 1</p>	<p>8,9,            18-20,            23-25,28</p>
A	<p>SCHERNTHANER G H ET AL: "Endothelial progenitor cells are reduced but activated in type 1 diabetic patients with longstanding disease and high HbA(1c)"            DIABETOLOGIA,            vol. 49, no. Suppl. 1,            September 2006 (2006-09), pages 726-727,            XP002484318            &amp; 42ND ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIABETES (EASD); COPENHAGEN, DENMARK;            SEPTEMBER 14 -17, 2006            ISSN: 0012-186X            abstract</p>	<p>1,10,11</p>

-/--

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/052578

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS [Online]            BIOSCIENCES INFORMATION SERVICE,            PHILADELPHIA, PA, US;            October 2006 (2006-10),            SCHEMTHANER GERIT ET AL: "Impaired number            and function of circulating endothelial            progenitor cells in patients with morbid            obesity"            XP002484322            Database accession no. PREV200700121516            abstract            &amp; CIRCULATION,            vol. 114, no. 18, Suppl. S,            October 2006 (2006-10), page 185,            79TH ANNUAL SCIENTIFIC SESSION OF THE            AMERICAN-HEART-ASSOCIATION; CHICAGO, IL,            USA; NOVEMBER 12 -15, 2006            ISSN: 0009-7322</p>	1,10,11
A	<p>-----</p> <p>LOOMANS C J M ET AL: "Endothelial            Progenitor Cell Dysfunction: A Novel            Concept in the Pathogenesis of Vascular            Complications of Type 1 Diabetes"            DIABETES 2004 US,            vol. 53, no. 1, January 2004 (2004-01),            pages 195-199, XP002484319            ISSN: 0012-1797            cited in the application            abstract            page 196, right-hand column, paragraph 1 -            page 198, right-hand column, paragraph 2</p>	1,10,11
A	<p>-----</p> <p>TEPPER O M ET AL: "Human endothelial            progenitor cells from type II diabetics            exhibit impaired proliferation, adhesion,            and incorporation into vascular            structures"            CIRCULATION 2002 US,            vol. 106, no. 22,            26 November 2002 (2002-11-26), pages            2781-2786, XP002484320            ISSN: 0009-7322            cited in the application            abstract            page 2783, right-hand column, last            paragraph - page 2786, left-hand column,            paragraph 2</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1,10,11

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/052578

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	OKAMOTO H: "Osteopontin and cardiovascular system" MOLECULAR AND CELLULAR BIOCHEMISTRY 200706 NL, vol. 300, no. 1-2, June 2007 (2007-06), pages 1-7, XP002484321 ISSN: 0300-8177 1573-4919 the whole document -----	1-31
P,X	ZHAO X ET AL: "Impairment of myocardial angiogenic response in the absence of osteopontin" MICROCIRCULATION 2007 US, vol. 14, no. 3, March 2007 (2007-03), pages 233-240, XP008092821 ISSN: 1073-9688 1549-8719 the whole document -----	1-31

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2008/052578

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 19-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No <b>PCT/EP2008/052578</b>
--

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 2006060779	A	08-06-2006	US 2006165667 A1	27-07-2006
WO 2007012764	A	01-02-2007	AU 2006273928 A1 CA 2616712 A1 EP 1913130 A2 FR 2889200 A1	01-02-2007 01-02-2007 23-04-2008 02-02-2007
WO 2006130690	A	07-12-2006	NONE	
JP 2004222836	A	12-08-2004	NONE	
WO 03046135	A	05-06-2003	AU 2002357748 A1 CA 2468020 A1 EP 1455841 A2 JP 2005519033 T	10-06-2003 05-06-2003 15-09-2004 30-06-2005
WO 2007024649	A	01-03-2007	NONE	
US 6414219	B1	02-07-2002	US 2002188962 A1	12-12-2002

专利名称(译)	骨桥蛋白用于预测和治疗心血管疾病		
公开(公告)号	<a href="#">EP2114422A1</a>	公开(公告)日	2009-11-11
申请号	EP2008717341	申请日	2008-03-03
[标]申请(专利权)人(译)	爱尔兰国立大学, 戈尔韦		
申请(专利权)人(译)	爱尔兰国立高威大学		
当前申请(专利权)人(译)	爱尔兰国立高威大学		
[标]发明人	OBRIEN TIMOTHY BARRY FRANK LIEW YIE LOONG AARON SAMALI AFSHIN DUFFY ANGELA		
发明人	O'BRIEN, TIMOTHY BARRY, FRANK LIEW YIE LOONG, AARON SAMALI, AFSHIN DUFFY, ANGELA		
IPC分类号	A61K35/12 C07K14/52 A61K38/19 C12N15/11 A61K48/00 G01N33/53 A61K49/00 C07K16/28 A61L27/22 A61K35/28 A61K35/44		
CPC分类号	A61K35/28 A61K35/44 A61P3/10 A61P9/00 A61P9/10		
优先权	20070136 2007-03-02 IE 20070901 2007-12-10 IE		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

用于预测和治疗心血管疾病的骨桥蛋白本发明涉及内皮祖细胞 ( EPC ) 和骨桥蛋白用于治疗心血管疾病或并发症的用途。本发明还涉及EPC骨桥蛋白水平作为这些心血管并发症发展风险的标志物的用途。特别地，本发明提供了基于骨桥蛋白和编码骨桥蛋白的基因的组合物和方法。